Viewing nowCombinationSitagliptin and Metformin Tablets 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.

MFDS item code 202204595 · Approved 2022.12.21 · Insurance code 642906710
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. The components sitagliptin and metformin act together to effectively lower blood sugar levels. Therefore, it improves blood sugar management and acts as an adjunct to diabetes treatment.
The dose of this drug for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this drug is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this drug for patients who cannot achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching to this drug from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient’s blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this drug. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be conducted. Patients with renal impairment This drug may be used, with the following dose adjustments, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains sitagliptin and metformin and is primarily used for the treatment of type 2 diabetes. Serious allergic reactions may occur during the use of this medication. If you experience symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck, inform your doctor immediately. Acute pancreatitis, which is a serious pancreatic inflammation, may also occur. Sudden abdominal pain, nausea, vomiting, or fever should prompt immediate medical attention. This medication should not be used in patients with impaired kidney function, severe infections, dehydration, acute myocardial infarction, sepsis, or other acute diseases. In such cases, the use of this medication should be discontinued. Particularly, before and after tests using radiologic contrast agents, this medication should be temporarily paused to protect kidney function, and should only be resumed after confirming normal kidney function post-examination. It is recommended that this medication not be used during pregnancy or in women who may become pregnant, as well as in breastfeeding women. During treatment with this medication, there is a risk of lactic acidosis, which is a rare but serious metabolic disorder. If you experience symptoms such as muscle pain, weakness, difficulty breathing, abdominal pain, or unusual drowsiness, inform healthcare professionals immediately. Additionally, elderly patients and those with reduced kidney function should have regular kidney function tests and dosage adjustments as necessary. This medication may cause hypoglycemia; therefore, caution is needed if meals are missed or excessive exercise is undertaken, and the risk of hypoglycemia may increase when taken with other antidiabetic medications. The consumption of alcohol during treatment may increase the risk of lactic acidosis, so it is advisable to avoid it. If surgery is planned, this medication should be discontinued 48 hours prior to the surgery and can be resumed once oral intake has resumed post-surgery and kidney function is confirmed to be normal. Regular blood sugar tests and kidney function tests are required during the usage of this medication, and blood tests are recommended as vitamin B12 deficiency may occur. If any unexpected side effects or symptoms occur during medication, it is important to consult healthcare professionals immediately.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent exposure to air. It is best to maintain the storage temperature between 1 and 30 degrees Celsius at room temperature to preserve the medication's efficacy.
Bright pink oval-shaped film-coated tablet
56 tablets/box [14 tablets/PTP x 4], 30 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.